Empagliflozin Attenuates Pulmonary Arterial Remodeling Through Peroxisome Proliferator-Activated Receptor Gamma Activation-Reference-Cited by-同舟云学术

Empagliflozin Attenuates Pulmonary Arterial Remodeling Through Peroxisome Proliferator-Activated Receptor Gamma Activation

Published:2024-08-01 Issue:9 Volume:7 Page:2725-2738
ISSN:2575-9108
Container-title:ACS Pharmacology & Translational Science
language:en
Short-container-title:ACS Pharmacol. Transl. Sci.

Author:

Lai Ying-Ju¹²³^ORCID,Yeh Yung-Hsin¹,Huang Yen-Lin⁴,De Almeida Celina²⁵,Chang Gwo-Jyh¹⁵^ORCID,Chen Wei-Jan¹,Hsu Hsao-Hsun⁶

Affiliation:

1. Cardiovascular Division, Chang Gung Memorial Hospital, Tao-Yuan 333, Taiwan

2. Department of Respiratory Therapy, Chang Gung University College of Medicine, Chang-Gung University, Tao-Yuan 33353, Taiwan

3. Department of Respiratory Care, Chang-Gung University of Science and Technology, Chia-Yi 61363, Taiwan

4. Department of Pathology, National Taiwan University Cancer Center and National Taiwan University College of Medicine, Taipei 106328, Taiwan

5. Graduate Institute of Clinical Medical Sciences, Chang Gung University College of Medicine, Tao-Yuan 33353, Taiwan

6. Division of Thoracic Surgery, Department of Surgery, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei 10002, Taiwan

Funder

Chang Gung Medical Foundation

Ministry of Science and Technology, Taiwan

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acsptsci.4c00127

Reference55 articles.

1. Haemodynamic definitions and updated clinical classification of pulmonary hypertension

2. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

3. Mechanisms of disease: pulmonary arterial hypertension

4. Molecular pathogenesis of pulmonary arterial hypertension

5. Histopathology of Primary Pulmonary Hypertension